The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Open accessAbstract
Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID‐19. All the patients had complete follow‐up to death or recovery. Severe COVID‐19 was defined by a 3‐level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID‐19 by multivariate and propensity score (PS)‐weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID‐19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty‐eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti‐CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with increased risk of severe COVID‐19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). Results were confirmed by the PS‐weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID‐19 pandemic persists. ANN NEUROL 2021;89:780–789
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2010) · University of Twente Research Information · Cited by 6,037
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229 · cited 1×
“…a defective response that, in people with severe COVID-19, may depend on various mechanisms including the presence of anti-interferon autoantibodies, 27 a genetically defective type I interferon response, 28,29 or the ability of SARS-CoV-2 to neutralize the antiviral effects of type I interferons.”
BackgroundOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021 · cited 1×
“…lower with rituximab compared to fi ngolimod and natalizumab; ocrelizumab clinical trials reported an increased risk of respiratory tract infections, 17,18 and safety issues emerged in diseases other than MS. 19 With respect to the association with treatment duration, it has been shown that…”
BackgroundOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 1×
“…with rituximab compared to fi ngolimod and natalizumab; ocrelizumab clinical trials reported an increased risk of respiratory tract infections, 17,18 and safety issues emerged in diseases other than MS. 19 With respect to the association with treatment duration, it has been shown that long-term…”
BackgroundA tutorial on propensity score estimation for multiple treatments using generalized boosted models
McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013) · Statistics in Medicine · doi:10.1002/sim.5753 · Cited by 1,450 · cited 1×
“The weights were calculated using an iterative robust approach based on the Generalized Boosted Model (GBM).(10) The balance among treatment groups was defined by the standardized mean difference, and the optimal GBM iteration was found by minimizing this quantity.”
MethodGenetic mechanisms of critical illness in COVID-19
The GenOMICC Investigators, Pairo-Castineira, E., The ISARIC4C Investigators, Initiative, T. C.-1. H. G., 23andMe Investigators, BRACOVID Investigators, Gen-COVID Investigators, Clohisey, S., Klaric, L., Bretherick, A. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03065-y · Cited by 1,365
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000768 · Cited by 1,223
Cited by
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 507
Salter, A., Fox, R. J., Newsome, S. D., Halper, J., Li, D. K. B., Kanellis, P., Costello, K., Bebo, B., Rammohan, K., Cutter, G. R., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0688 · Cited by 267
Sparks, J. A., Wallace, Z. S., Seet, A. M., Gianfrancesco, M. A., Izadi, Z., Hyrich, K. L., Strangfeld, A., Gossec, L., Carmona, L., Mateus, E. F., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220418 · Cited by 238
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Metadata
- Authors
- Sormani, M. P., De Rossi, N., Schiavetti, I., Carmisciano, L., Cordioli, C., Moiola, L., Radaelli, M., Immovilli, P., Capobianco, M., Trojano, M., Zaratin, P., Tedeschi, G., Comi, G., Battaglia, M. A., Patti, F., Salvetti, M., & the Musc‐19 Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2021-02-09
- Volume
- 89
- Issue
- 4
- Pages
- 780-789
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3121831652
- Cited by
- 447
- References
- 34
- FWCI
- 59.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.